The U.S. Food and Drug Administration has approved a pre-filled pen for injecting Peg-Intron® (peginterferon alfa-2b) to treat hepatitis C.
Schering-Plough's Redipen® is the first and only pen delivery system approved for administering pegylated interferon therapy. The pen is designed to be simpler to use than a traditional vial and syringe, allowing patients to administer Peg-Intron in three easy steps.
Patients mix their dose of Peg-Intron with sterile water by pushing down on the pen to combine the two, both of which are stored in the pen. Patients then use a dial on the pen to accurately select their predetermined individualized dose for injection.
The Redipen will be available in four different strengths: 50, 80, 120 and 150 mcg, each indicated by a color-coded label and dosing button. An instructional videotape and brochure for use by patients and healthcare professionals will also be available.
The Redipen is expected to be available in the United States in early 2004.
Other sources: Schering-Plough